The latest Investing Matters Podcast episode with multi-award-winning fund manager and international bestselling author Lee Freeman-Shor has just been released. Listen here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
I appreciate that it seems to be a done deal but that does not improve my sense of either injustice or deprivation.Our value excludes most of the potential upside from Advair & none of it from our prospective Ellipta range generics & not even sure it includes the $32mill due soon from Pacira.
Pushing out expections from 2022 to second half 2022 in respect of "normalisation" of Flutifirm sales is pathetic & no mention of our fledgling CDMO business was probably an oversight
I agree MrBB. The outcome is as I suspected but doesn't mean I am happy with it.
The only consolation one can take is that, with the resources at their disposal, big Pharma could easily have made a counter offer with loose change found down the back of their corporate sofas if it really was the screaming bargain that it appears (to us) to be.
Have enjoyed the debates I have had on here. Good luck to all.
John
Have not posted here before but have a modest holding. Having banked the dividend I'm thinking of selling in the market.
After the RNS today can't see any counter offer coming along. Any views?
I certainly concur that we appear to have been significantly short changed on the price. I have been here through SKP 18 odd years and build a quite significant holding. I can't help but feel only this years added value is in the offer price, but certainly not beyond and echo BB and John's thoughts on this...
Hayashi -
Oops - hadn't finished before my clumsy finger sent that last one...
Hayashi - I have sold in chunks since the announcement, but was holding a big slice for a counter offer. Doesn't seem to be coming and I have put in a sell order for the remainder today - @ £1.37 so unlikely to be executed, but it looks like anything above the offer price now will be a bonus...
I sold about 40% of my holding in the market for 5/6p premium & should have sold the lot !
Chances of counter offer now v slim
Many thanks. Looks to be somewhat opportunistic lowball bid. Will probably exit.